


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the December 2013 NCCN Trends™ Survey, which focused on Chronic Lymphocytic Leukemia. This survey was sent to U.S. and International users of NCCN.org.


## DEMOGRAPHICS

**Distribution of Respondent Types (n = 780)**




Note: Percentages may not total 100 because of rounding.

**Q1. Do you treat patients with Chronic Lymphocytic Leukemia (CLL)? (n = 675)**





**Q2. What proportion of your CLL patients receive an anti-CD20 antibody as part of first-line treatment? (n = 321)**





**Q2. What proportion of your CLL patients receive an anti-CD20 antibody as part of first-line treatment?**

**By Geography**





**Q2. What proportion of your CLL patients receive an anti-CD20 antibody as part of first-line treatment?**

**By Practice Size**





**Q2. What proportion of your CLL patients receive an anti-CD20 antibody as part of first-line treatment?**

**By Practice Setting**




**Q2. What proportion of your CLL patients receive an anti-CD20 antibody as part of first-line treatment?**

**By Specialty**




**Q3. As new agents become available, do you expect to modify anti-CD20 antibody usage in first-line treatment for patients with CLL? (n = 317)**



**Q3. As new agents become available, do you expect to modify anti-CD20 antibody usage in first-line treatment for patients with CLL?**

**By Geography**

- Yes, decrease by 10+%
- Yes, decrease by < 10%
- No change
- Yes, increase by < 10%
- Yes, increase by 10+%






**Q3. As new agents become available, do you expect to modify anti-CD20 antibody usage in first-line treatment for patients with CLL?**

**By Practice Size**


- Yes, decrease by 10+%
- Yes, decrease by < 10%
- No change
- Yes, increase by < 10%
- Yes, increase by 10+%



**Q3. As new agents become available, do you expect to modify anti-CD20 antibody usage in first-line treatment for patients with CLL?**

**By Practice Setting**


- Yes, decrease by 10+%
- Yes, decrease by < 10%
- No change
- Yes, increase by < 10%
- Yes, increase by 10+%




**Q3. As new agents become available, do you expect to modify anti-CD20 antibody usage in first-line treatment for patients with CLL?**

**By Specialty**

- Yes, decrease by 10+%
- Yes, decrease by < 10%
- No change
- Yes, increase by < 10%
- Yes, increase by 10+%





**Q4. How satisfied are you with the currently available treatment options for patients with CLL? (n = 322)**



**Q4. How satisfied are you with the currently available treatment options for patients with CLL?**


**By Geography**



**Q4. How satisfied are you with the currently available treatment options for patients with CLL?**

**By Practice Size**


- Very unsatisfied
- Somewhat unsatisfied
- Neutral
- Somewhat satisfied
- Very satisfied



**Q4. How satisfied are you with the currently available treatment options for patients with CLL?**

**By Practice Setting**


- Very unsatisfied
- Somewhat unsatisfied
- Neutral
- Somewhat satisfied
- Very satisfied



**Q4. How satisfied are you with the currently available treatment options for patients with CLL?**


**By Specialty**

- Very unsatisfied
- Somewhat unsatisfied
- Neutral
- Somewhat satisfied
- Very satisfied






**Q5. Do you utilize minimum residual disease (MRD) to assess patient responses to treatment? (n = 316)**



**Q5. Do you utilize minimum residual disease (MRD) to assess patient responses to treatment?**

**By Geography**

- Yes, regularly
- Occasionally
- No, never




**Results: December 2013**  
CHRONIC LYMPHOCYTIC LEUKEMIA

**Q5. Do you utilize minimum residual disease (MRD) to assess patient responses to treatment?**

**By Practice Size**

- Yes, regularly
- Occasionally
- No, never




**Results: December 2013**  
CHRONIC LYMPHOCYTIC LEUKEMIA

**Q5. Do you utilize minimum residual disease (MRD) to assess patient responses to treatment?**

**By Practice Setting**

- Yes, regularly
- Occasionally
- No, never




**Results: December 2013**  
CHRONIC LYMPHOCYTIC LEUKEMIA

**Q5. Do you utilize minimum residual disease (MRD) to assess patient responses to treatment?**

**By Specialty**

- Yes, regularly
- Occasionally
- No, never



**NCCN Trends™** is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

**Christine MacCracken, MSHEd, BSN**  
**Senior Director, Business Insights**  
**215.690.0557**  
[maccracken@nccn.org](mailto:maccracken@nccn.org)

## **National Comprehensive Cancer Network® (NCCN®)**

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.



National  
Comprehensive  
Cancer  
Network®

275 Commerce Drive • Suite 300  
Fort Washington, PA, 19034  
Telephone: 215.690.0300  
Fax: 215.690.0280

[NCCN.org](http://NCCN.org) - For Clinicians • [NCCN.org/patients](http://NCCN.org/patients) - For Patients

\*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.